TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin
Nov 20, 2021•41 min•Ep. 831
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Scott Hammer on TWiV 52
- Meeting for molnupiravir EUA (FDA)
- SARS-CoV-2 reinfection associates with antibodies (Clinical Inf Dis)
- AFM surveillance in US (CDC)
- Monoclonal antibody treatment in high-risk patients (J Inf Dis)
- Letters read on TWiV 831
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android